Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976

Authors Colombo G, Caruggi M, Di Matteo S, Rossi A

Published 5 December 2008 Volume 2008:4(6) Pages 1283—1283

DOI https://doi.org/10.2147/NDT.S5342


Erratum

Colombo GL, Caruggi M, Di Matteo, et al. 2008. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976.

Page 972, Results, right column, last paragraph. The second sentence should read:

In the simulated cohort of 1000 patients, the values with aripiprazole for 26 weeks showed the avoidance of 34 events of diabetes over 5 years (28 in discounted scenario), resulting in total cost savings of €1,933.24 (€1,472.52 in discounted scenario).

Page 973, Table 5:

Under Events avoided/1000 schizophrenia patients (5 years): 18 should read 28.

Under Cost/metabolic syndrome avoided (5 years): −€2,860.52 should read −€1,852.73.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]